The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. The ...

The approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in ...

This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...

Our analysis of ecdysone-induced downstream targets reveals that overexpression of the nuclear receptor E75, particularly facilitates the malignant transformation of benign tumors. Genome-wide DNA ...

Lewis Mitchell receives funding from the Australian Research Council and Australian Department of Defence. Melissa Humphries receives funding from the Australian Department of Defence. Jono Tuke ...

Ocaliva targets the farnesoid X receptor (FXR) to reduce bile acid production and promote its removal. Ocaliva’s scrutiny comes at a time of a new arrival in the PBC space. The FDA granted accelerated ...

Human epidermal growth factor receptor 2 (HER2) proteins are found on the surface of breast cells and are involved in normal cell growth. Too much HER2 protein, however, can cause some types of breast ...

during which a panel of outside experts nearly unanimously voted against Intercept’s request for a full approval of its farnesoid X receptor agonist. During the meeting, 13 of the FDA’s ...

About Ocaliva ® (obeticholic acid) OCALIVA, a farnesoid X receptor (FXR) agonist, is indicated for the treatment of adult patients with primary biliary cholangitis (PBC) without cirrhosis or with ...

MORRISTOWN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced ...